Previous close | 337.15 |
Open | 335.19 |
Bid | 335.33 x 1200 |
Ask | 335.49 x 900 |
Day's range | 334.44 - 338.51 |
52-week range | 249.98 - 361.41 |
Volume | |
Avg. volume | 1,268,104 |
Market cap | 127.69B |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | 40.63 |
EPS (TTM) | 8.26 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | 3.20 (0.95%) |
Ex-dividend date | 27 Mar 2024 |
1y target est | 372.04 |
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evaluate the expected performance of Stryker (SYK) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.